NCT02991612View on ClinicalTrials.gov

Rifaximin in Patients With Gastroesophageal Variceal Bleeding

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 25, 2016

Primary Completion Date

December 22, 2017

Study Completion Date

February 28, 2018

Conditions
CirrhosisEsophageal and Gastric VaricesGastrointestinal Hemorrhage
Interventions
DRUG

Rifaximin

Patients receive Rifaximin 400mg bid for 2 months

Trial Locations (1)

200032

180 Fenglin Road, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT02991612 - Rifaximin in Patients With Gastroesophageal Variceal Bleeding | Biotech Hunter | Biotech Hunter